Bullforlyfe
Posted - 14 hours ago
$EDSA Seems like Edesa have filed the IND with the FDA for EB06: Anti-CXCL10 Monoclonal Antibody. Trial - Moderate to Severe Non-Segmental (Generalized) Vitiligo. In a mid November update to the presentation, Page 16 has changed to 'In Progress' from 'Readying'.... Well, at least something is in play...
TheGhostOfEd
Posted - 1 day ago
$EDSA Just sucks that the share price is such in the shitter. I love this as an entry point for new investors here. All the good possibilities remain. It's just a long ass investment horizon.
EireTrader
Posted - 1 day ago
$EDSA ...
Cinicaltrials.gov updated for both EB01 and EB05.
EB05... Suspended for Business Reasons not safety concerns.
The refinement of EB01 target population from Chronic ACD to Moderate/Severe Chronic ACD is interesting.
HopehelpsU
Posted - 1 day ago
$EDSA I gotta back in Edesa soon. There's going to be a huge day here. One day. What day? WTF knows?
HopehelpsU
Posted - 1 day ago
$EDSA IMG...
Trump is buying my BKKT! UP 150%!!!
pausiloy
Posted - 1 day ago
$EDSA let's compare the pipeline progress intepreted by EDSA and IFRX, you can see why EDSA is such a scam, IFRX honestly present the progress of ARDS P2, but EDSA make the progress look like 50% completed
TheGhostOfEd
Posted - 2 days ago
$EDSA What it's going to take tho, imo, is at least one clear cut Phase 2 with truly positive results with no trial fack ups. Let's hope that the future pulmonary fibrosis trial can yield these sorts of results. A positive trial is game on so to speak. Positioning EB05 as a follow on indication for chronic repirstory diseases such as IPF (which many ARDS patients go on to develop) is smart and obvious low hanging fruit. Hopefully they also spend the next year determining the back drop for the next indication beyond that or perhaps even look to another asset or work to expand the use on EB01. Everything is potentially in play.
TheGhostOfEd
Posted - 2 days ago
$EDSA I still believe in EB05s long term potential. I might be batshit crazy but I remain thoroughly convinced that EB05 has multi indication / platform potential, well beyond just the current respiratory related uses. While I'm not entirely sure Edesa will be the ones to truly unlock the value on EB05, eventually it will get into the right hands and hopefully to the great benefit of existing shareholders and patients alike. I hope that in 2025 thst Edesa, in addition to their expected clinical and corporate milestones, will make a concerted effort to build awareness of EB05 and it's potential broad use. For example, I believe there maybe enough supportive evidence to even try a subcutaneous formulation as a standalone treatment or in conjunction with semaglutide for obesity. Now wouldn't that be something? That's just the tip of the iceberg. They should be selling the dream at all these conferences. You never know when the right person from the right company is watching...
TheGhostOfEd
Posted - 2 days ago
$EDSA Pump gonna come fairly soon I think. Just curious where it takes us. H5N1. Buckle your seatbelts.
TheGhostOfEd
Posted - 2 days ago
$EDSA Edesa presenting at LSX tomorrow at 12:30pm GMT. Hopefully they brought in the big guns. Presentation might be up on the website in the AM. Probably just their normal pitch deck. Best of luck!
TheGhostOfEd
Posted - 2 days ago
$EDSA https://www.usaspending.gov/award/CONT_AWD_75A50124C00001_7505_-NONE-_-NONE- BARDA Trial funding scaling up....hopefully news to come on this front very very soon.
TheGhostOfEd
Posted - 2 days ago
$EDSA EB05 is definitely "down" but not "out". I'm really still left scratching my head about the P3. Even if recruitment remained very slow, why pause the trial heading into peak enrollment season with the grant still available and being used? Why not just wait until the spring of 2025 and assess where you stand? Was there any perceived benefits to stopping it now? I feel like we have to be missing a key element. Some random ideas: - Patient enrollment skewed too elderly potentially corrupting any data readout - Decided to pull existing EB05 inventory to use for BARDA trial - Meaningful patient enrollment milestone hit, IA forthcoming but just not yet disclosed to investors - Concerns about commercial viability of covid related therapeutics causing them to pivot - Positive engagements with regulators/SIF in respect to rather expanding scope of trial or receiving additional funding Thoughts?
TheGhostOfEd
Posted - 2 days ago
$EDSA I really think pursuing the Vitiligo indication is smart. There have been major transactions in the space and the approved therapy opzelura is good but not great and not w/o potentially severe side effects. Altho it's ease of administration does win out vs EB06 (currently). Vitiligo also has a fairly high population prevalence and being a cosmetic issue, people will spend big money to potentially fix it. Furthermore, the cost to complete the P2 can likely be self funded. It's unlikely in my view that they would partner pre P2 but I guess if the interest and money is there, it's possible, but not my base case. Lastly, I think the data from the future trial is less subjective vs other derma indications....you'll rather see repigmentation/improvement or not. Long story short while most of us are here for EB05, a positive P2 data readout for EB06 in the next 2 years (or sooner) could unlock significant value.
TheGhostOfEd
Posted - 2 days ago
$EDSA On that note, I am very bullish on EB06s potential. Based on its MoA and the animal studies I feel that it will have a moderately high probability (say 70%) of showing some level of clinical benefit in the future P2. My only concern is the IV method of administration on a biweekly basis. While not a major impediment, it could prove to be a drawback if ever commercialized, and could increase patient drop off or churn during the trial. I feel like they should figure out the subcutaneous formulation first and take that route for the P2. I'd hate to see another scenario where they go IV for the P2 and then look to switch to SC for the P3 only to face regulatory hurdles.
TheGhostOfEd
Posted - 2 days ago
$EDSA Obviously it's not helpful that XBI got clocked this week, but definitely part of the issue here is zero enthusiasm around Edesa from the market, current, and prospective investors. With the P3 on hold, EB01 sitting and waiting for a partnership, and EB07 / EB06 waiting their respective INDS, I think once we see the resumption of clinical activities we'll see some renewed interest.
TheGhostOfEd
Posted - 3 days ago
$EDSA The 11/1 AHs volume +, was most likely ATM. Between existing cash, Par's investment, some ATM, and maybe another draw down on the grant before they paused the trial should give them enough on the books to avoid going concern language in the upcoming 10K. Nevertheless the share price has been crippled so they definitely find themselves in a tough spot. Hopefully they have taken their foot off the ATM pedal and kept dilution to a minimum, other than required. Total existing cash should buy them some goodwill time until next summer at minimum. Could also have to pay LC some money for EB05 if they didn't have enough inventory on hand. We'll find out.
Bullforlyfe
Posted - 3 days ago
$EDSA OMG! I’ll never doubt Par again, THIS explains EVERYTHING … finally EDSA strategy makes sense 🤩 Genius really when you think about it!
TheGhostOfEd
Posted - 4 days ago
$EDSA Could the company possibly capitalize on this bird flu scare?
TheGhostOfEd
Posted - 4 days ago
$EDSA Keep thinking about the BARDA trial....what's going on with that? A year to announce and almost another six months and zip. I know it's government work but damn. I feel like maybe a positive surprise there? P2 graduating to P3? Unlikely but it feels like somethings afoot.
Bullforlyfe
Posted - 4 days ago
$EDSA Caligula appointing his horse as a senator in the Roman senate doesn’t seem so ridiculous anymore… https://www.bbc.com/news/articles/cp3nzp782ejo
AllPenniesNoDividends
Posted - 4 days ago
$EDSA Now my average is $15.12… guess I’ll keep adding 100 shares here and there to get it down to like $14 if I’m lucky after about a year 🤦♂️🤦♂️
AllPenniesNoDividends
Posted - 4 days ago
$EDSA Small average down for me at $2.16… I guess I’ll take it but def not adding large amounts yet
TheGhostOfEd
Posted - 4 days ago
$EDSA Conference on Monday? Bet. Down 10% Minimum $1.85 close. $1.50 by end of next week. $1.00 and below by December. Headed straight to zero.
TheGhostOfEd
Posted - 4 days ago
$EDSA $1s next week!!!
TheGhostOfEd
Posted - 4 days ago
$EDSA Sorry I should have said bankruptcy by end of year....
TheGhostOfEd
Posted - 4 days ago
$EDSA Penny stock by December, reverse split next summer.
TheGhostOfEd
Posted - 4 days ago
$EDSA Every day down 4-8%.....every....single....day.... $0 forthcoming.
TheGhostOfEd
Posted - 4 days ago
$EDSA Every "conference" they do they go down 5%.
TheGhostOfEd
Posted - 4 days ago
$EDSA Down 50% in the last month. Incredible.